Lipocine Inc stock is traded at $1.59, with a volume of 208,114. It is up 0.00% in the last 24 hours and down -4.22% over the past month. Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Previous Close:
$1.59
Open:
$1.62
24h Volume:
208,114
Relative Volume:
0.88
Market Cap:
$17.61M
Revenue:
$2.00M
Net Income/Loss:
-$11.43M
P/E Ratio:
-
EPS:
-$1.96
Net Cash Flow:
-$10.05M
1W Performance:
+3.92%
1M Performance:
-4.22%
6M Performance:
-31.76%
1Y Performance:
-45.55%
1-Day Range:
$1.56$1.64
1-Week Range:
$1.50$1.74
52-Week Range:
$1.36$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine IncSector
HealthcareIndustry
BiotechnologyPhone
801 994 7383Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS